Formulas, treatments, toolkits and dosage forms used to treat inflammation (including atomic dermatitis) or cancer include an effective drug component. The preparation methods provided include particles, which include: trace active ingredients； one or more granular polymers； one or more filling materials； one or more isolates； and one or more antioxidants. Treatment includes oral active ingredient management for patients with atomic dermatitis.The active ingredients ranged from about 20 mg to 80 mg. 1. Characteristic 1: A pharmaceutical preparation for the treatment of one or more diseases characterized by the deregulation of SYK/JAK (including granules), including: trace active ingredients； one or more granular polymers； and one or more substances. Filled； one or more isolates； and one or more antioxidants, the active ingredient is a prescription compound (1) or an acceptable salt on a drug, a corresponding isomer or a corresponding isomer, where R1 is a ring (2) containing six prescription members.H, o h, C (o) o h, tar C832183318326 or C8331832626cn； and R2 are benzene rings (3) in the formulation.There, R83088 is a ring with six formulas (4) members.Among them, R8309ES N or CH and R8310s are a hydroxyl group, a methyl methanol group, or an ethanol group. The degradation level of API in the formulation does not exceed 0.6% of the total active ingredients after storage in 1 ml. ANA 40 degree C/75% HR is packed in an open container. Claim 23: Statement of claim 14, in which the active ingredient is 2-(1-(4-((4-) (4-) (4-(4-) (hydroxypyridine-1-il) aniline) -5-oxo-5, 6-dihydropirimido [4, 5-d] piridazin-2-il) piperidin-4-il. Proposition 24: The expression of Proposition 14,The active ingredients are 2 - (1 - (4 - (4 - (2 -)(4 - (2 -) (hydroxyl) - phenyl - 1 - il) amino - 5 - Oxo - 5, 6 - dihydropirimido [4, 5 - d] piridazin - 2 - il) piperidin - 4 - il) acetone. Requirement 38: A method of stabilizing drug formulations that can help treat one or more diseases that a
